In RMS, concomitant inhibition of the RAS/MEK/ERK and PI3K/AKT/mTOR pathways has recently been demonstrated in two independent studies to synergistically trigger apoptosis and to inhibit tumor growth in vivo (19, 20). Here, MAP2K7 is linked to neoplasm.